Posaconazole: An extended-spectrum triazole antifungal agent

Clinical Therapeutics

Volumn 29, Issue 9, 2007, Pages 1862-1886

  Schiller, Daryl S ^a   Fung, Horatio B ^b  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

graft vs host disease; invasive fungal infections; neutropenia; oropharyngeal candidiasis; posaconazole

Indexed keywords

AMPHOTERICIN B; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DISOPYRAMIDE; DOCETAXEL; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; LIDOCAINE; NEVIRAPINE; PACLITAXEL; PHENYTOIN; POSACONAZOLE; QUINIDINE; RIFABUTIN; SILDENAFIL; TACROLIMUS; TRICYCLIC ANTIDEPRESSANT AGENT; VINCA ALKALOID; VORICONAZOLE;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; BILIARY TRACT DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LONG TERM CARE; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; MYCOSIS; NAUSEA; OPPORTUNISTIC INFECTION; OROPHARYNX CANDIDIASIS; SIDE EFFECT; VOMITING;

ADMINISTRATION, ORAL; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 36749026613     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.09.015     Document Type: Article

References (142)

1. Wisplinghoff H., Bischoff T., Tallent S., et al. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study [published corrections appear in Clin Infect Dis. 2004;39:1093 and Clin Infect Dis. 2005;40:1077]. Clin Infect Dis. 39 (2004) 309-317
2. Beck-Sague C., Jarvis W., and the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 167 (1993) 1247-1251
3. Anaissie E., Bodey G., and Rinaldi M. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 8 (1989) 323-330
4. Groll A., Shah P., Mentzel C., et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33 (1996) 23-32
5. Groll A., and Walsh T. Uncommon opportunistic fungi: New nosocomial threats. Clin Microbiol Infect 7 Suppl 2 (2001) 8-24
6. Fleming R., Walsh T., and Anaissie E. Emerging and less common fungal pathogens. Infect Dis Clin North Am. 16 (2002) 915-933
7. Fleming R., Walsh T., and Anaissie E. Emerging and less common fungal pathogens. Infect Dis Clin North Am. 16 (2002) vi-vii
8. Aperis G., Myriounis N., Spanakis E., and Mylonakis E. Developments in the treatment of candidiasis: More choices and new challenges. Expert Opin Investig Drugs 15 (2006) 1319-1336
9. Schering-Plough news release. Schering-Plough announces FDA approval of NOXAFIL ® (posaconazole) for prevention of invasive fungal infections (September 2006), Schering-Plough, Kenilworth, NJ. http://www.scheringplough.com/schering_plough/news/release.jsp?releaseID=906202 Available at: Accessed January 10, 2006
10. NoxaFil ® [package insert] (2006), Schering Corporation, Kenilworth, NJ
11. Bennett F., Saksena A., Lovey R., et al. Hydroxylated anaIogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole (Sch 56592; 2 or [S,S]-5). Bioorg Med Chem Lett 16 (2006) 186-190
12. Hof H. A new, broad-spectrum azole antifungal: Posaconazole-mechanisms of action and resistance, spectrum of activity. Mycoses 49 Suppl 1 (2006) 2-6
13. Xiao L., Madison V., Chau A., et al. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 48 (2004) 568-574
14. Ghosal A., Hapangama N., Yuan Y., et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 32 (2004) 267-271
15. Munayyer H., Mann P., Chau A., et al. Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds. Antimicrob Agents Chemother 48 (2004) 3690-3696
16. Reference method for broth dilution antifungal susceptibility testing of yeasts (2002), Clinical and Laboratory Standards Institute, Wayne, Pa Approved standard-second edition (MA27-A2)
17. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi (2002), Clinical and Laboratory Standards Institute, Wayne, Pa Approved standard (MA38-A)
18. Sabatelli F., Patel R., Mann P., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50 (2006) 2009-2015
19. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., et al. Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 50 (2006) 917-921
20. Pfaller M., Messer S., Hollis R., et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 42 (1998) 3242-3244
21. Pfaller M., Messer S., Boyken L., et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbial Infect Dis 48 (2004) 201-205
22. Pfaller M., Messer S., Hollis R., and Jones R. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 45 (2001) 2862-2864
23. Pfaller M., Diekema D., Jones R., et al., SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbial 40 (2002) 852-856
24. Ostrosky-Zeichner L., Rex J., Pappas P., et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
25. Pfaller M., Diekema D., Messer S., et al., International Fungal Surveillance Participant Group. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbial 41 (2003) 78-83
26. Barchiesi F., Tortorano A., Di Francesca L., et al. Genotypic variation and antifungal susceptibilities of Candida pelliculosa clinical isolates. J Med Microbial 54 (2005) 279-285
27. Pfaller M., Messer S., Gee S., et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbial 37 (1999) 870-872
28. Pfaller M., Messer S., Boyken L., et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbial 43 (2005) 2163-2167
29. Yildiran S., Fothergill A., Sutton D., and Rinaldi M. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses 45 (2002) 378-383
30. Guinea J., Pelaez T., Alcala L., et al. Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: Analysis by site of isolation. Antimicrob Agents Chemother 49 (2005) 3495-3497
31. Manavathu E., Cutright J., Loebenberg D., and Chandrasekar P. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46 (2000) 229-234
32. Diekema D., Messer S., Hollis R., et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphoteritin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41 (2003) 3623-3626
33. Pfaller M., Messer S., Hollis R., Jones R., and SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergiflus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46 (2002) 1032-1037
34. Dannaoui E., Meletiadis J., Tortorano A., et al., EBGA Network. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients. J Med Microbial 53 (2004) 129-134
35. Carrillo A., and Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 45 (2001) 2151-2153
36. Meletiadis J., Meis J., Mouton J., et al., EUROFUNG Network. In vitro activities of new and conventional antifungal agents against clinical Scedosporiurn isolates. Antimicrob Agents Chemother 46 (2002) 62-68
37. Sun Q., Fothergill A., McCarthy D., et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 46 (2002) 1581-1582
38. Manavathu E., Abraham O., and Chandrasekar P. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posacanazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus. Clin Microbial Infect 7 (2001) 130-137
39. Petraitiene R., Petraitis V., Groll A., et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia. Antirnicrob Agents Chemother 45 (2001) 857-869
40. Graybill J., Bocanegra R., Najvar L., et al. SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 42 (1998) 539-542
41. Walsh T., Petraitis V., Petraitiene R., et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: Pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 188 (2003) 305-319
42. Kirkpatrick W., McAtee R., Fathergill A., et al. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemotker 44 (2000) 780-782
43. Imai J., Singh G., Clemons K., and Stevens D. Efficacy of posaconazole in a murine model of central nervous system aspergillosis [published correction appears in Antimicrob Agents Chemother. 2004;48:4931]. Antimicrob Agents Chemother 48 (2004) 4063-4066
44. Graybill J., Hernandez S., Bocanegra R., and Najvar L. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob Agents Chemother 48 (2004) 3715-3719
45. Hernandez S., Gonzalez G., McCarthy D., et al. Alternatives to amphotericin B for Candida rugosa infection. J Antimicrob Chemother 54 (2004) 477-480
46. Cacciapuoti A., Loebenberg D., Corcoran E., et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 44 (2000) 2017-2022
47. Perfect J., Cox G., Dodge R., and Schell W. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 40 (1996) 1910-1913
48. Barchiesi F., Schimizzi A., Caselli F., et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 48 (2001) 769-773
49. Barchiesi F., Spreghini E., Schimizzi A., et al. Posaconazole and amphotericin 13 combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother 48 (2004) 3312-3316
50. Connolly P., Wheat J., Schnizlein-Bick C., et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother 43 (1999) 322-328
51. Connolly P., Wheat L., Schnizlein Bick C., et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 44 (2000) 2604-2608
52. Sugar A., and Liu X. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 40 (1996) 1314-1316
53. Lozano-Chiu M., Arikan S., Paetznick V., et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 43 (1999) 589-591
54. Sun Q., Najvar L., Bocanegra R., et al. In vivo activity of posaconazole against Mucor spp. in an immuno-suppressed-mouse model. Antimicrob Agents Chemother 46 (2002) 2310-2312
55. Dannaoui E., Meis J., Loebenberg D., and Verweij P. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 47 (2003) 3647-3650
56. Lutz J., Clemons K., Aristizabal B., and Stevens D. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 41 (1997) 1558-1561
57. Gonzalez G., Tijerina R., Najvar L., et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 46 (2002) 1352-1356
58. Al-Abdely H., Najvar L., Bocanegra R., and Graybill J. Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob Agents Chemother 49 (2005) 1701-1707
59. AI-Abdely H., Najvar L., Bocanegra R., et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob Agents Chemother 44 (2000) 1159-1162
60. Molina J., Martins-Filho O., Brener Z., et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 44 (2000) 150-155
61. AI-Abdely H., Graybill J., Loebenberg D., and Melby P. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 43 (1999) 2910-2914
62. Soczo G., McNicholas P., Kardos G., et al. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, Calif. Further studies on fungicidal activities of posaconazole (2006) Abstract 1596
63. Espinel-Ingroff A., Fothergill A., Peter J., et al. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 40 (2002) 3204-3208
64. Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 45 (2001) 605-607
65. Oakley K., Moore C., and Denning D. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 41 (1997) 1124-1126
66. Andes D., Marchillo K., Conklin R., et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 48 (2004) 137-142
67. Manavathu E., Ramesh M., Baskaran I., et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 53 (2004) 386-389
68. Barchiesi F., Schimizzi A., Caselli F., et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 44 (2000) 2435-2441
69. Oliveira E., Fothergill A., Kirkpatrick W., et al. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob Agents Chemother 49 (2005) 3544-3545
70. Barchiesi F., Schimizzi A., Najvar L., et al. Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob Agents Chemother 45 (2001) 1355-1359
71. Perea S., Gonzalez G., Fothergill A., et al. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 40 (2002) 1831-1833
72. Cacciapuoti A., Halpern J., Mendrick C., et al. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother 50 (2006) 2587-2590
73. Cacciapuoti A., Gurnani M., Halpern J., et al. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob Agents Chemother 49 (2005) 638-642
74. Najvar L., Cacciapuoti A., Hernandez S., et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: Comparative studies in two laboratories. Antimicrob Agents Chemother 48 (2004) 758-764
75. Mann P., Parmegiani R., Wei S., et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother 47 (2003) 577-581
76. Nomeir A., Kumari P., Hilbert M., et al. Pharmacokinetics of SCH 56592, a new azole broad-spectrum anti-fungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 44 (2000) 727-731
77. Ezzet F., Wexler D., Courtney R., et al. Oral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 44 (2005) 211-220
78. Saha P., and Kou J. Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers. Eur J Pharm Biopharm 50 (2000) 403-411
79. Courmey R., Pai S., Laughlin M., et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 47 (2003) 2788-2795
80. Gubbins P., Krishna G., Sansone-Parsons A., et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 50 (2006) 1993-1999
81. Ullmann A., Comely O., Burchardt A., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 50 (2006) 658-666
82. Courtney R., Wexler D., Radwanski E., et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57 (2004) 218-222
83. Sansone-Parsons A., Krishna G., Calzetta A., et al. Effect of a nutritional supplement on posaconazole pharmacokinetics Following oral administration to healthy volunteers. Antimicrob Agents Chemother 50 (2006) 1881-1883
84. Courtney R., Radwanski E., Lim J., and Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 48 (2004) 804-808
85. Krieter P., Flannery B., Musick T., et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 48 (2004) 3543-3551
86. Pitisuttithum P., Negroni R., Graybill J., et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56 (2005) 745-755
87. Lodge B., Ashley E., Steele M., and Perfect J. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol 42 (2004) 1376-1378
88. Sponsel W., Graybill J., Nevarez H., and Dang D. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 86 (2002) 829-830
89. Courtney R., Sansone A., Smith W., et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 45 (2005) 185-192
90. Wong-Beringer A., and Kriengkauykiat J. Systemic antifungal therapy: New options, new challenges. Pharmacotherapy 23 (2003) 1441-1462
91. Ashley E., Lewis R., Lewis J., et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 43 Suppl 1 (2006) S28-S39
92. Kim H., Kumari P., Laughlin M., et al. Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma. J Chromatogr A 987 (2003) 243-248
93. Wexler D., Courtney R., Richards W., et al. Effect of posaconazole on cytochrome P450 enzymes: A randomized, open-label, two-way crossover study. Eur J Pharm Sci 21 (2004) 645-653
94. Sansone-Parsons A., Krishna G., Simon J., et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 51 (2007) 495-502
95. Ullmann A., Lipton J., Vesole D., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease [published correction appears in N Engl J Med. 2007;357:428]. N Engl J Med 356 (2007) 335-347
96. Cornely O., Maertens J., Winston D., et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
97. Schering-Plough news release. Schering-Plough announces FDA approval of NOXAFIL® (posaconazole) for treatment of oropharyngeal candidiasis (OPC). Kenilworth, NJ: Schering-Plough; October 2006. Available at: http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=919520. Accessed January 10, 2006.
98. Skiest D., Vazquez J., Anstead G., et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 44 (2007) 607-614
99. Vazquez J., Skiest D., Nieto L., et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 42 (2006) 1179-1186
100. Anstead G., Martinez M., and Graybill J. Control of a Candida glabrata prosthetic endovascular infection with posaconazole. Med Mycol 44 (2006) 273-277
101. Tobon A., Correa A., Arango M., et al. Posaconazole therapy for severe abdominal candidiasis: A case report. Rev Iberoam Micol 21 (2004) 79-81
102. Walsh T., Raad I., Patterson T., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 44 (2007) 2-12
103. Garbino J., Uckay I., Amini K., et al. Absidia posttraumatic infection: Successful treatment with posaconazole. J Infect 51 (2005) e135-e138
104. Brugiere O., Dauriat G., Mal H., et al. Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: Recovery after posaconazole therapy. Transplantation 80 (2005) 1361-1362
105. Gilman A., Serrano A., Skelley J., and Zwick D. Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant. Pediatr Blood Cancer 47 (2006) 959-963
106. Rutar T., and Cockerham K. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am J Ophthalmol 142 (2006) 187-188
107. Tobon A., Arango M., Fernandez D., and Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: Recovery after posaconazole therapy. Clin Infect Dis 36 (2003) 1488-1491
108. Simmons J., Zeitler P., Fenton L., et al. Rhinocerebral mucormycosis complicated by internal carotid artery thrombosis in a pediatric patient with type 1 diabetes mellitus: A case report and review of the literature. Pediatr Diabetes 6 (2005) 234-238
109. Paul S., Marty F., and Colson Y. Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole. Ann Thorac 5urg 82 (2006) 338-340
110. Greenberg R., Mullane K., van Burik J., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 50 (2006) 126-133
111. Page II R., Schwiesow J., and Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: Case report and review of the literature. Pharmacotherapy 27 (2007) 290-298
112. De Decker K., Van Poucke S., Wojciechowski M., et al. Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis. Pediatr Crit Care Med 7 (2006) 482-485
113. Ferguson T., Schniederjan S., Dionne-Odorn J., et al. Posaconazole for Apophysomyces elegans rhino-orbital zygomycosis following trauma for a male with well-controlled diabetes. J Clin Microbiol 45 (2007) 1648-1651
114. McGinnis M. Chromoblastomycosis and phaeohyphomycosis: New concepts, diagnosis, and mycology. J Am Acad Dermatol 8 (1983) 1-16
115. Herbrecht R., Letscher-Bru V., Fohrer C., et al. Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B. Eur J Clin Microbiol Infect Dis 21 (2002) 814-817
116. Mellinghoff I., Winston D., Mukwaya G., and Schiller G. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 34 (2002) 1648-1650
117. Proia L., and Trenholme G. Chronic refractory phaeohyphomycosis: successful treatment with posaconazole. Mycoses 49 (2006) 519-522
118. Negroni R., Helou S., Petri N., et al. Case study: Posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 38 (2004) e15-e20
119. Negroni R., Tobon A., Bustamante B., et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 47 (2005) 339-346
120. Pujol I., Guarro J., Gene J., and Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother 39 (1997) 163-167
121. Herbrecht R., Kessler R., Kravanja C., et al. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 23 (2004) 1451-1454
122. Tu E., McCartney D., Beatty R., et al. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 143 (2007) 222-227
123. Raad I., Hachem R., Herbrecht R., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 42 (2006) 1398-1403
124. Catanzaro A., Cloud G., Stevens D., et al. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Canada. Safety and tolerance of posaconazole in patients with non-meningeal disseminated coccidioidomycosis (2000) Abstract 1417
125. Anstead G., Corcoran G., Lewis J., et al. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 40 (2005) 1770-1776
126. Clark B., Foster R., Tunbridge A., and Green S. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect 51 (2005) e177-e180
127. Restrepo A., Tobon A., Clark B., et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 54 (2007) 319-327
128. Raad I., Graybill J., Bustamante A., et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 42 (2006) 1726-1734
129. Sansone A., Belle D., and Statkevich P. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Effect of posaconazole on the pharmacokinetics of tacrolimus in healthy volunteers (2003) Abstract A-1603
130. Mantadakis E., Amoiridis G., Kondi A., and Kalmanti M. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol Oncol 29 (2007) 130
131. Courtney R., Statkevich P., and Laughlin M. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. Effect of posaconazole on the pharmacokinetics of cyclosporine (2001) Abstract 27
132. Michalets E. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18 (1998) 84-112
133. Courmey R., Statkevich P., and Laughlin M. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. Potential for a drug interaction between posaconazole and phenytoin (2001) Abstract 28
134. Courtney R., Statkevich P., and Laughlin M. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. Potential for a drug interaction between posaconazole and rifabutin (2001) Abstract 29
135. Courtney R., Wexler D., and Statkevich P. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, Calif. Effect of cimetidine on the pharmacokinetics of posaconazole in healthy volunteers (2002) Abstract 1838
136. Noxafil [summary of product characteristics] (March 2007), Schering-Plough Europe, Brussels, Belgium
137. 2007 Drug Topics Red Book (2007), Thomson Medical Economics, Montvale, NJ
138. Vfend [package insert] (2006), Pfizer Inc, New York, NY
139. Herbrecht R., Denning D., Patterson T., et al., Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N EngI J Med 347 (2002) 408-415
140. Girijavallabhan V., Bennett F., Saksena A., et al. Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Sch 59884, a water-soluble prodrug of Sch 56592 for intravenous formulation (1999) Abstract 1932
141. Loebenberg D., Menzel F., Corcoran E., et al. Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. SCH 59884, the intravenous prodrug of the antifungal triazole SCH 56592 (1999) Abstract 1933
142. Jeu L., Piacenti F., Lyakhovetskiy A., and Fung H. Voriconazole. Clin Ther 25 (2003) 1321-1381